Advertisement

ADVERTISEMENT

CAR-T therapy

HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
12/17/2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses...
12/17/2020
Journal of Clinical Pathways
Conference Coverage
Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL
12/06/2020
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with...
12/06/2020
Journal of Clinical Pathways
News
CMS Hospital IPPS Proposed Rule Includes CAR-T Reimbursement Updates
05/13/2020
The Centers for Medicare & Medicaid Services (CMS) has released its proposed Hospital Inpatient Prospective Payment System (IPPS) rule for 2021. Included in the proposed rule is a new Medicare Severity-Diagnosis...
The Centers for Medicare & Medicaid Services (CMS) has released its proposed Hospital Inpatient Prospective Payment System (IPPS) rule for 2021. Included in the proposed rule is a new Medicare Severity-Diagnosis...
The...
05/13/2020
Journal of Clinical Pathways
News
Long-Term Outcomes of High-Dose CAR-T Therapy for Relapsed, Refractory CLL
05/12/2020
Chimeric antigen receptor T-cell targeting CD-19 (CAR T-19) may be more effective at a higher dose (5 x 108) than a standard lower dose (5 x 107) in patients with relapsed or refractory chronic lymphocytic leukemia...
Chimeric antigen receptor T-cell targeting CD-19 (CAR T-19) may be more effective at a higher dose (5 x 108) than a standard lower dose (5 x 107) in patients with relapsed or refractory chronic lymphocytic leukemia...
...
05/12/2020
Journal of Clinical Pathways
Research in Review
New Therapy Highly Effective in Treatment-Resistant CLL
07/18/2017
JCP Editors
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A...
07/18/2017
Journal of Clinical Pathways
Research in Review
CAR-T Therapy Highly Effective in Treatment-Resistant CLL
07/18/2017
JCP Editors
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A recent study reported an overall response rate (ORR) of 71% in patients with chronic lymphocytic leukemia (CLL) treated with anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy after prior treatment...
A...
07/18/2017
Journal of Clinical Pathways
Research in Review
Immune Checkpoint Inhibitors May Increase Response to CAR-T Therapy in ALL
05/19/2017
JCP Editors
Pembrolizumab improves response to chimeric antigen receptor (CAR) T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia (ALL), according to research that will be presented at...
Pembrolizumab improves response to chimeric antigen receptor (CAR) T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia (ALL), according to research that will be presented at...
...
05/19/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use